|
| Treatment | Cell type | Effects on ncRNAs | Outcomes | References |
|
| Aspirin (5 mM) | Human umbilical vein endothelial cells) HUVECs( | Downregulation of miR-155 | Downregulation of eNOS and NF-κB | [3] |
| Aspirin (1 mM) | MKN-45 cells (gastric cancer cell line) | Downregulation of miR-21 | Upregulation of PPARα, downregulation of VEGFR2 phosphorylation and AKT | [8] |
| Aspirin (1 mM)+apatinib (0.1 mM) | MKN-45 cells (gastric cancer cell line) | Downregulation of miR-21 | Upregulation of PPARα, downregulation of VEGFR2 phosphorylation, AKT, migration and colony formation | [8] |
| Aspirin (100 μM) | Colorectal cancer cells (primary and cell lines) | Upregulation of lncRNA OLA1P2 | Upregulation of FOXD3, activating STAT3 pathway | [9] |
| Aspirin (10 mM) | LS174T cells (colorectal cancer cell line) | Downregulation of miR-21 | Downregulation of Wnt/β-catenin/TCF4 signaling | [10] |
| Aspirin (5 mM) | MDA-MB-231, MCF-7, SK-BR-3, and HEK293T cells (breast cancer cell lines) | Downregulation of lncRNA H19 | Downregulation of PDK1, glycolysis, glucose uptake, lactate production, ATP levels and stem-like cancer characteristics | [46] |
| Aspirin (0.5 and 1 mM)+fluvastatin (5 μM) | MCF10.AT1 and MCF10.DCIS cells (MCF10A-based model for breast cancer) | Upregulation of miR-140-3p-1 | Downregulation of HMGCR and HMGCS1 | [47] |
| Aspirin (200 ppm) | MCF-7 (breast cancer cells) | Upregulation of miR-222, miR-98, and miR-145 | Downregulation of Bcl-xl | [49] |
| Aspirin (100 μL) | MKN-45 cells (gastric cancer cell line) | Downregulation of miR-4670-5P | — | [50] |
| Aspirin (1600 mg/kg) | Lung of mice | Downregulation of miR-30e, miR-32, miR-380, and miR-543 | Downregulation of proliferation by non-prostaglandin-dependent pathways | [52] |
| Aspirin (1600 mg/kg) | Serum of mice | Downregulation of miR-16, miR-133, miR-137, and miR-191 | Downregulation of proliferation affects non-prostaglandin-dependent pathways | [52] |
| Aspirin (1600 mg/kg) | Lung and serum of mice | Downregulation of miR-30c, miR-181b, miR-183, miR-301a, miR-350, miR-466a-3p, miR-466i-3p, miR-500, and miR-709 | Downregulation of proliferation by non-prostaglandin-dependent pathways | [52] |
| Aspirin (1 mM) | Human NSCLC cell lines H460 and H1299 cell line | Upregulation of miR-101 and let-7 miRNA family | COX-2, IL-1β-mediated repression of miR-101, IL-1β-mediated activation of Lin28B, cell proliferation, and migration | [55] |
| Aspirin (2.5 mM and 5 mM) | A549 and H1299 lung cancer cell lines | Upregulation of miR-98 | Downregulation of WNT1 | [56] |
| Aspirin (5 mM) | Human thyroid cancer cell lines (TPC-1 and K-1) | Downregulation of lncRNA H19 | Downregulation of estradiol and ERβ | [58] |
| Aspirin (2.5 μmol/mL) | Non-SP and SP cells isolated from MHCC-97L cell line | Upregulation of miR-491 | Downregulation of ABCG2 protein expression | [59] |
| Aspirin (4 mM) | C666-1 cell line (nasopharyngeal carcinoma cells) | Downregulation of BART miRNAs | Downregulation of NF-κB activity | [61] |
Aspirin (300 mg and 100 mg)+clopidogrel (300 mg and 75 mg)
Aspirin+ticagrelor (180 mg and 90 mg)
Aspirin+clopidogrel+cilostazol (100 mg) | Platelet-rich plasma of CAD patients | Upregulation of miR-365-3p | Upregulation of platelet activity | [62] |
| Aspirin (100 mg)+clopidogrel (300 mg) | Blood samples of CAD patients | Upregulation of miR-126, miR-130a, miR-142, and miR-27 | — | [63] |
| Aspirin low dose (75-100 mg)+clopidogrel (300–600 and 75 mg) | Plasma CAD patients | Downregulation of miR-223 | — | [65] |
| Aspirin (75 and 300 mg)+prasugrel (10 mg) | Platelets of patients | Downregulation of miR-223, miR-191, miR-126, and miR-150 | Downregulation of platelet | [68] |
| Aspirin (100 mg)+indomethacin (200 μmol/L) | Platelets of healthy males | Downregulation of miR-19b-1-5p | — | [70] |
| Aspirin (100 mg/day)+clopidogrel (75 mg/day)+ticagrelor (90 mg/BD) | Plasma of patients | Downregulation of miR-126, miR-150, and miR-223, upregulation of and miR-96 | — | [71] |
| Aspirin (330 μmol/L) | Plasma or platelet of healthy volunteers | Downregulation of miR-126 | — | [72] |
| Aspirin (100 and 300 mg/day, 50 μmol/L) | Human platelets and DAMI cells (human megakaryoblastic) | Downregulation of miR-21 | Upregulation of MRP4 and PPARα | [74] |
| Aspirin (100 mg/day) | Platelets of atherothrombotic patients | Downregulation of miR-135a-5p and miR-204-5p | — | [76] |
| Aspirin (100 mg/day) | Platelets of patients | Downregulation of miR-26b | Upregulation of MRP4 | [78] |
| Aspirin (75 and 100 mg, 150 mg/day) | Plasma of patients | Downregulation of miR-92a | Aspirin resistance | [80] |
| Aspirin (1000 mM)+DHA (1000 mM) | SH-Y5Y cell line | Downregulation of miR-21 | Upregulation of PPARα and RXRa, PSD-95, BDNF, GDNF, downregulation of NF-κB and COX-2 | [83] |
| AT-RvD1 (150 ng/eye; 5 μL drop) | Corneal cells of mice | Downregulation of miR-223, miR-155, and miR-132 | Downregulation of proinflammatory mediators such as IL1β, IL6, and IL-12, as well as MIP-2, MCP-2, CXCL1, VEGF, and MMP9 | [91] |
| AT-RvD1 (5 μg/kg) | Liver of rats | Upregulation of miR-146b | Downregulation of TRAF6 and NF-κB, ALT, AST, and liver tissue damage, amelioration of TNFα and myeloperoxidase | [110] |
| Aspirin (3 mg/day)+atorvastatin (0.25 mg/day) | Myocardial cells of rats | Downregulation of miR-21 | Improvement of radiation-induced changes in the Cx43, improvement of oxidative stress and inflammation | [112] |
|
